Bergen, Norway 8 August 2022

Independent experts from the European Commission's Innovation Radar have
reviewed Lifecares technology in the EU funded project FORGETDIABETES. The
review concludes that Lifecare's innovations are "Market Ready" and considered
among the top 14% of innovations in scientific projects receiving financial
grants from the European Commission.

Lifecare's involvement in the project FORGETDIABETES involves two key
innovations:  
1.	Lifecare AS is responsible for the development and customization of
Lifecare's proprietary osmotic pressure-based sensor for glucose monitoring in
the subcutaneous area, into an "implantable intra peritoneal sensor". The sensor
represents a critical component for the development of an artificial pancreas. 

2.	Lifecare Laboratory GmbH is a project participant - independent of the mother
company - responsible for the development of an in-vitro test system for the
sensor and an insulin pump as part of the planned artificial pancreas. As part
of this task, Lifecare Laboratory have developed an "In-vitro test bench for
dynamic interference testing of glucose sensors".

Both inventions have been reviewed and categorized as "Market ready" with a
"high" market creation potential by the European Commission's Innovation Radar. 

Read more in Lifecares newsletter:
https://lifecare.no/news/information-from-lifecare-august-2022/


This is Lifecare 
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The sensor is currently subject of pilot clinical
testing. The Company's patented technology also has the potential for use in
various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE). 

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Joacim Holter, CEO at Lifecare
AS, on 08.08.22 at 08:30 CET.